Wirtz Stefan, Neurath Markus F
Laboratory of Immunology, I. Medical Clinic, University of Mainz, Mainz, Germany.
J Clin Invest. 2005 Mar;115(3):586-8. doi: 10.1172/JCI24518.
Recently, type I interferons IFN-alpha and IFN-beta (IFN-alpha/beta) have been evaluated in pilot clinical trials for the treatment of active ulcerative colitis. However, the underlying mechanisms that may contribute to a potential therapeutic effect are incompletely understood. A new study in this issue demonstrates a protective role for IFN-alpha/beta, induced by activation of a Toll-like receptor 9-dependent pathway, in a rodent model of experimental colitis.
最近,I型干扰素α和β(IFN-α/β)已在治疗活动性溃疡性结肠炎的初步临床试验中进行了评估。然而,可能促成潜在治疗效果的潜在机制尚未完全了解。本期的一项新研究表明,在实验性结肠炎的啮齿动物模型中,由Toll样受体9依赖性途径激活诱导的IFN-α/β具有保护作用。